Omnicell (NASDAQ:OMCL) Updates FY24 Earnings Guidance

Omnicell (NASDAQ:OMCL - Get Free Report) issued an update on its FY24 earnings guidance on Thursday morning. The company provided EPS guidance of $0.90-1.40 for the period, compared to the consensus EPS estimate of $1.07. The company issued revenue guidance of $1.05-1.12 billion, compared to the consensus revenue estimate of $1.06 billion. Omnicell also updated its Q2 guidance to $0.10-0.20 EPS.

Omnicell Price Performance

Shares of Omnicell stock traded up $2.12 during trading on Thursday, hitting $29.29. The stock had a trading volume of 604,883 shares, compared to its average volume of 536,559. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of -65.09 and a beta of 0.77. Omnicell has a 12 month low of $25.69 and a 12 month high of $77.14. The business's 50-day moving average is $27.67 and its 200 day moving average is $31.88. The company has a current ratio of 2.52, a quick ratio of 2.22 and a debt-to-equity ratio of 0.48.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its earnings results on Thursday, February 8th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.22. Omnicell had a negative net margin of 1.78% and a positive return on equity of 3.43%. The company had revenue of $258.85 million during the quarter, compared to analyst estimates of $256.00 million. As a group, sell-side analysts anticipate that Omnicell will post 0.09 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have issued reports on OMCL. Wells Fargo & Company cut their price target on shares of Omnicell from $28.00 to $26.00 and set an equal weight rating for the company in a research report on Friday, February 9th. Benchmark restated a buy rating and set a $38.00 price target on shares of Omnicell in a research report on Tuesday. Finally, Barclays began coverage on shares of Omnicell in a research report on Wednesday, January 3rd. They set an underweight rating and a $33.00 price target for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of Hold and a consensus target price of $42.20.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.